Clinical Trials Logo

Filter by:
NCT ID: NCT05014828 Active, not recruiting - Clinical trials for Advanced Solid Tumor

To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Patients With Selected Solid Tumors

Start date: September 18, 2021
Phase: Phase 2
Study type: Interventional

This study includes 2 parts. Part 1 is a safety run-in stage and part 2 is to assess the efficacy and safety of tislelizumab in combination with lenvatinib

NCT ID: NCT05014815 Active, not recruiting - Clinical trials for Nonsmall Cell Lung Cancer, Stage IV

Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer

Start date: November 16, 2021
Phase: Phase 2
Study type: Interventional

This is a randomized investigator and participant blinded, sponsor unblinded, multicenter study that evaluates the safety and efficacy of ociperlimab with tislelizumab and histology-based chemotherapy compared with treatment with tislelizumab and histology-based chemotherapy in participants with previously untreated locally advanced, unresectable, or metastatic NSCLC

NCT ID: NCT05012449 Active, not recruiting - Tibial Fracture Clinical Trials

Transitional Ankle Fracture Management Using a New Joystick Technique

Transitional
Start date: July 1, 2021
Phase: N/A
Study type: Interventional

To investigate the feasibility and short-term clinical efficacy of the arthrography-assisted joystick technique for the treatment of adolescent transitional ankle fracture.

NCT ID: NCT05010694 Active, not recruiting - Kirsten Rat Sarcoma Clinical Trials

Dose Finding Study of GH35 in Patients With Advanced Solid Tumors

Start date: September 27, 2021
Phase: Phase 1
Study type: Interventional

Evaluate the safety and tolerability of GH35 in patients with KRAS mutant advanced solid tumors. Estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D) in patients with KRAS mutant advanced solid tumors.

NCT ID: NCT05010434 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

Sintilimab and Bevacizumab Combined With Radiotherapy for Advanced Hepatocellular Carcinoma

Start date: August 16, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate both the efficacy and safety of sintilimab combined with bevacizumab and radiotherapy in advanced hepatocellular carcinoma.

NCT ID: NCT05009329 Active, not recruiting - Solid Tumor Clinical Trials

A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China

Start date: July 26, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

To assess safety, tolerability, PK, efficacy and determine recommended phase 2 dose (RP2D) of JAB-21822 (glecirasib) administered in adult participants with KRAS p.G12C-mutant advanced solid tumors.

NCT ID: NCT05009069 Active, not recruiting - Rectal Cancer Clinical Trials

A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer

Start date: March 18, 2022
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy and safety of atezolizumab plus tiragolumab or atezolizumab alone following neoadjuvant chemoradiotherapy (nCRT) in participants with locally advanced rectal cancer (LARC). The study consists of a safety run-in phase and a randomization phase. Participants enrolled in the safety run-in phase will receive atezolizumab + tiragolumab following nCRT. Upon determination of the safety of the treatment regimen, the study will be proceed to the randomization phase. Participants will be randomized in a 1:1 ratio to the atezolizumab + tiragolumab arm or atezolizumab arm.

NCT ID: NCT05008783 Active, not recruiting - Clinical trials for Gastric Adenocarcinoma

A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma

Start date: September 17, 2021
Phase: Phase 3
Study type: Interventional

A randomized, Double-blind, Multicenter, phase III Clinical Study of Comparing the Efficacy and Safety of AK104 Plus Oxaliplatin and Capecitabine (XELOX) Versus Placebo Plus XELOX as First-line Treatment for locally advanced Unresectable or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma.

NCT ID: NCT05007262 Active, not recruiting - Clinical trials for Diabetic Retinopathy

Tangningtongluo Tablet in the Treatment of Non-proliferative Diabetic Retinopathy

Start date: August 31, 2021
Phase: Phase 2
Study type: Interventional

This trial is planned to collect relevant clinical data to evaluate the prevention efficacy and safety of Tangningtongluo tablets on the non-proliferation period of diabetic retinopathy.

NCT ID: NCT05007093 Active, not recruiting - Clinical trials for DTC - Differentiated Thyroid Cancer

Study on the Treatment of Differentiated Thyroid Carcinoma With Anlotinib

Start date: December 1, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy of anlotinib in patients with locally advanced or metastatic differentiated thyroid cancer resistant to iodine therapy.